Published in
Wiley, Cancer, 16(116), p. 3903-3909, 2010
DOI: 10.1002/cncr.25264
Links
- ORCID
- ORCID
- Wiley
- [www.ncbi.nlm.nih.gov] | PDF
- [europepmc.org] | PDF
- [www.researchgate.net] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
Tools
Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer
Journal article published in 2010 by
Suresh S. Ramalingam,
R. Donald Harvey 
,
Nabil Saba,
Taofeek K. Owonikoko ,
John Kauh,
Dong M. Shin,
Shi-Yong Sun,
Sandra Strychor,
Mourad Tighiouart,
Merrill J. Egorin,
Haian Fu,
Fadlo R. Khuri
,
Nabil Saba,
Taofeek K. Owonikoko ,
John Kauh,
Dong M. Shin,
Shi-Yong Sun,
Sandra Strychor,
Mourad Tighiouart,
Merrill J. Egorin,
Haian Fu,
Fadlo R. Khuri
This paper is available in a repository.
Full text: Download
Published version:
archiving forbidden
Data provided by 